Clinical Trial Update: Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial evaluates the safety of combining CX-5461 (Pidnarulex) with Trastuzumab Deruxtecan (T-DXd) in patients with HER2-positive and relate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Low Breast Cancer

Drugs mentioned

• CX-5461 (CX-5461)
• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Status: RECRUITING